Imaging Endpoints is contributing to a new Nature publication showing that Quantitative MRI of vascular disrupting agents may aid cancer drug development.
To read the full study, visit https://www.nature.com/articles/s41598-020-71246-w.
Imaging Endpoints was founded to Connect Imaging to the Cure™
Imaging Endpoints was founded to Connect Imaging to the Cure™ and is making its vision a reality with a record year for supporting numerous regulatory approvals of new, life-saving oncology drugs for adults and children. To read more about how our… Read More
Imaging Endpoints is involved in extensive and cutting-edge COVID-19 imaging
We are offering the detection and standardized recording of the clinical and radiological disease features of COVID-19 infection, Radiomic Analysis, CD8+ Analysis and AI Analysis of SARS-CoV-2 for clinical trials. For more information, see https://imagingendpoints.com/covid-19/covid-analysis/
Big iData: Imaging Endpoints is uniquely positioned to house millions of images across multiple disease types in searchable databases that enable deep imaging research and development.
Our novel technology enables us to structure, de-identify and search radiology reports and their associated images in order to select datasets for specific, targeted research projects. Longitudinal patient data combined with our AI analysis provides opportunity for development of early… Read More
Imaging Endpoints is very thankful to be experiencing growth and hiring during this challenging time.
We are seeking exceptional talent for dynamic positions in numerous areas of our Company. Imaging Endpoints is a team of diverse and driven professionals with a goal to change the world by Connecting Imaging to the Cure. Learn more about… Read More
